Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 11th International Conference on Vascular Dementia .

Day 1 :

Keynote Forum

Hans Von Holst

Karolinska University Hospital, Sweden

Keynote: A new hypothesis on the etiology to Dementia in Traumatic Brain Injury and Stroke

Time : 10:00- 10:45 AM

Vascular Dementia 2019 International Conference Keynote Speaker Hans Von Holst photo

Hans von Holst received his MD´s degree in 1976 and specialist in Neurosurgery 1982, Karolinska University Hospital. In 1985 he earned his PhD and Associate Professorship in Neurosurgery, Clinical Neuroscience, Karolinska Institutet and appointed as senior neurosurgeon 1988 - 2015. During 1991-1996 he was Chairman of the Dept of Neurosurgery and Division Manager of the Neuroclinics at Karolinska University Hospital, respectively. Between 1994-2014 he was appointed as Professor in Neuroengineering, KTH Royal Institute of Technology and visiting Professor at Karolinska Institutet 2006-2012, He has published over 150 original papers in reputed journals, reviews and books including editorial board member in several journals.


Increased intracellular water content defined as cytotoxic brain tissue edema is a serious secondary clinical complication to traumatic brain injury (TBI) and stroke and without knowledge to the etiology. Recently a hypothesis to the nervous tissue edema was presented suggesting that external dynamic and internal mechanical static impact forces caused protein unfolding resulting in an increased brain tissue water content and what happens with the metabolism in the long run. The hypothesis was confirmed by computer simulation tests. In this laboratory study we further evaluated the hypothesis by using the mature protein laminin LN521 upon the effects of both dynamic as well as static impact forces, respectively. The treated laminin solutions were then analyzed with denatured electrophoresis and Electron Microscopy showing aggregation and fragmentation of the laminin structures. The present laboratory results confirm earlier hypothesis and computer simulation suggesting for the first time that dynamic impact force in an accident and increased mechanical static force in stroke unfold mature proteins having the potential to increase the intracellular water content defined as cytotoxic brain tissue edema. The clinical condition resembles the phenomenon when elasmobranchs including white sharks prevent their cells from too high hydrostatic pressure in the deep sea. Thus, the present laboratory study results and knowledge from marine physics may be considered to improve the clinical treatment and outcome of TBI and stroke patients. This opens up new perspectives how vascular dementia in TBI and Stroke should be looked upon when it come sto clinical treatment.


Keynote Forum

Anne L. Foundas

Brain Institute of Louisiana, USA

Keynote: Vascular cognitive impairment: treatment innovation

Time : 10:45-11:30

Vascular Dementia 2019 International Conference Keynote Speaker Anne L. Foundas photo

Dr. Foundas is a Cognitive and Behavioral Neurologist currently working as the Executive Director of the Brain Institute of Louisiana. She has worked as Professor of Neurology at Tulane University, Vice-Chair of Clinical Research at LSU, and Chair of Neurology at UMKC. Her clinical practice focuses on patients with cognitive disorders. Her research addresses questions about speech and language, motor control, learning and memory. She has published over 200 scientific papers


The world population is aging. It is estimated that by 2050 there will be over 1.6 billion people worldwide aged 65 and over (17% of the world’s population). The greatest risk for dementia is increasing age. Vascular dementia (VaD) is one dementia subtype that occurs with increasing age. This diagnosis is found in about 20% of people with dementia. Many people with neurodegenerative diseases, like Alzheimer’s disease or Frontotemporal dementia, have microvascular disease and meet the clinical criteria for a mixed-type of dementia. These mixed-dementia patients often have a more malignant progression of their disease compared to individuals without microvascular disease. Our clinical and research team focuses on early intervention in individuals with mild cognitive impairment, including innovative treatment approaches to change the trajectory of cognitive decline. This talk will be divided into three parts. The first part will include an overview of the clinical and pathological heterogeneity of VaD. The second part will emphasize clusters of patients with vascular cognitive impairment, including major cognitive markers that seem to be prevalent across clinical subtypes. Finally, the third part will present preliminary data regarding our clinical approach that includes the innovative use of neural stimulation and photobiomodulation. Our clinical research team uses a two-pronged approach to:

(1) improve communication skills and functional independence in patients with a dementia diagnosis,

(2) facilitate early identification and treatment of at risk individuals. This discussion will focus on our innovative treatment approaches designed to enhance functional independence, improve communication skills, and reduce caregiver burden. 

Break: Networking & Refreshment Break 11:30-11:50 @TBA

Keynote Forum

Brian Norris

Founder, Executive Director Living Memories C.I.C.UK

Keynote: Archival materials are increasingly being incorporated into products and interventions as part of practice with older people

Time : 11:50 -12:35 PM

Vascular Dementia 2019 International Conference Keynote Speaker Brian Norris  photo

Brian is Executive Director of DiSC. An international media lawyer and digital media practitioner by background, he is managing the company and overseeing the development of the Living Memories and Heartwise+ projects.



Archival materials are increasingly being incorporated into products and interventions as part of practice with older people. One area of this work involves the use of archival films, videos, photographs, and television and radio broadcasts in tools for reminiscence activities with older people, in particular individuals living with dementia.Interest in the well-being benefits of this work is based on the demonstrated ability of these multi-sensory materials to stimulate memories of the past in the person with dementia, and to afford opportunities for increasing communication and social interaction with caregivers and others.One current application of archival film for reminiscence activities is the project being developed by Liv, drawing on a major proprietary archive covering social and industrial life in Britain from the 1940s onwards. It was a Finalist in the national UK Nursing Times Awards 2017. This presentation, including screening of examples of archive film, will describe the development of digital tools being produced from this material including a series of DVDs and an accompanying reminiscence guide of topics and questions for use by family members and practitioners. It will also discuss the interactive online platform being developed for the delivery of Living Memories reminiscence resources on mobile devices. Issues such as the tailoring of content to particular audiences, for example, men who may struggle to engage with more generically-targeted social activities for persons with dementia, will also be addressed. Experiences to date of employing these tools in settings such memory cafés, and with a variety of professional and other user groups will be reported. A related Twitter feed (@memorytriggers) to help younger people communicate with those who grew up in the 1940s-60s will also be described.


Keynote Forum

Shu G. Chen

Case Western Reserve University School of Medicine, USA

Keynote: Peripheral Protein Aggregates as Biomarkers for Neurodegenerative Diseases

Time : 12:35 -13:10 PM

Vascular Dementia 2019 International Conference Keynote Speaker Shu G. Chen photo

Shu G. Chen, PhD, received his PhD in 1992 from the State University of New York at Buffalo, New York, USA. He is an Associate Professor of Pathology and Neurology at Case Western Reserve University School of Medicine. His research centers on the pathogenesis of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders. He has published more than 80 papers in scientific journals.



Neurodegenerative diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are characterized by the deposition of misfolded protein aggregates in the central nervous system (CNS). Previous efforts have focused on the development of CNS-proximal clinical biomarkers, including PET neuroimaging and cerebrospinal fluid measures of alpha-synuclein, beta-amyloid and tau. However, these diagnostic techniques are often used in clinical studies on patients with advanced disease state, and are complex, invasive or expensive. Therefore, there remains an urgent need for reliable, inexpensive and minimally invasive peripheral biomarkers. Recent studies have revealed widespread peripheral involvement of PD- and AD-like pathology, often prior to clinical manifestations of the diseases. Indeed, alpha-synuclein and tau deposits have been observed in peripheral tissues in PD and AD, respectively. A formidable challenge is that the levels of these amyloidogenic protein aggregates in peripheral tissues are extremely low and thus only variably detectable using immunological methods. Therefore, highly sensitive analytical platforms are required as the new generation of biomarker assays specific for protein aggregates and amyloid fibrils. The real-time quaking induced conversion (RT-QuIC) has emerged as a robust, rapid and ultrasensitive technology for template-assisted amplification of misfolded protein aggregates in neurodegenerative diseases. Using the RT-QuIC technique, our recent studies have shown that disease-associated protein aggregates are readily detectable in peripheral tissues of patients affected by PD, dementia with Lewy bodies, and AD and other tauopathies. Validation of peripheral protein biomarkers will enable sensitive premortem diagnostic tests for PD, AD, and related disorders, and accelerate clinical trials for disease-modifying therapies.


Break: Lunch Break 13:10-14:00 @TBA